Once the center of a public storm of anger over denied drug, Chimerix now can’t even recruit patients for their trials

Five years after Chimerix found itself at the center of a hurricane of public anger over its initial refusal to provide their lead experimental drug to a dying child, the biotech says now that they can’t even recruit patients for their studies.